Literature DB >> 18276844

IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.

Christian S Hinrichs1, Rosanne Spolski, Chrystal M Paulos, Luca Gattinoni, Keith W Kerstann, Douglas C Palmer, Christopher A Klebanoff, Steven A Rosenberg, Warren J Leonard, Nicholas P Restifo.   

Abstract

IL-2 and IL-21 are closely related cytokines that might have arisen by gene duplication. Both cytokines promote the function of effector CD8(+) T cells, but their distinct effects on antigen-driven differentiation of naive CD8(+) T cells into effector CD8(+) T cells are not clearly understood. We found that antigen-induced expression of Eomesodermin (Eomes) and maturation of naive CD8(+) T cells into granzyme B- and CD44-expressing effector CD8(+) T cells was enhanced by IL-2, but, unexpectedly, suppressed by IL-21. Furthermore, IL-21 repressed expression of IL-2Ra and inhibited IL-2-mediated acquisition of a cytolytic CD8(+) T-cell phenotype. Despite its inhibitory effects, IL-21 did not induce anergy, but instead potently enhanced the capacity of cells to mediate tumor regression upon adoptive transfer. In contrast, IL-2 impaired the subsequent antitumor function of transferred cells. Gene expression studies revealed a distinct IL-21 program that was characterized phenotypically by increased expression of L-selectin and functionally by enhanced antitumor immunity that was not reversed by secondary in vitro stimulation with antigen and IL-2. Thus, the efficacy of CD8(+) T cells for adoptive immunotherapy can be influenced by opposing differentiation programs conferred by IL-2 and IL-21, a finding with important implications for the development of cellular cancer therapies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18276844      PMCID: PMC2396726          DOI: 10.1182/blood-2007-09-113050

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  64 in total

1.  Skewed maturation of memory HIV-specific CD8 T lymphocytes.

Authors:  P Champagne; G S Ogg; A S King; C Knabenhans; K Ellefsen; M Nobile; V Appay; G P Rizzardi; S Fleury; M Lipp; R Förster; S Rowland-Jones; R P Sékaly; A J McMichael; G Pantaleo
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

2.  Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes.

Authors:  N Manjunath; P Shankar; J Wan; W Weninger; M A Crowley; K Hieshima; T A Springer; X Fan; H Shen; J Lieberman; U H von Andrian
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

Review 3.  Progress in human tumour immunology and immunotherapy.

Authors:  S A Rosenberg
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

4.  IL-21 promotes differentiation of naive CD8 T cells to a unique effector phenotype.

Authors:  Kerry A Casey; Matthew F Mescher
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

5.  Analysis of gamma c-family cytokine target genes. Identification of dual-specificity phosphatase 5 (DUSP5) as a regulator of mitogen-activated protein kinase activity in interleukin-2 signaling.

Authors:  Panu E Kovanen; Andreas Rosenwald; Jacqueline Fu; Elaine M Hurt; Lloyd T Lam; Jena M Giltnane; George Wright; Louis M Staudt; Warren J Leonard
Journal:  J Biol Chem       Date:  2002-11-14       Impact factor: 5.157

Review 6.  Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses.

Authors:  Julia Parrish-Novak; Donald C Foster; Richard D Holly; Christopher H Clegg
Journal:  J Leukoc Biol       Date:  2002-11       Impact factor: 4.962

7.  IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity.

Authors:  Marion T Kasaian; Matthew J Whitters; Laura L Carter; Leslie D Lowe; Jason M Jussif; Bijia Deng; Kaley A Johnson; JoAnn S Witek; Mayra Senices; Richard F Konz; Andrea L Wurster; Debra D Donaldson; Mary Collins; Deborah A Young; Michael J Grusby
Journal:  Immunity       Date:  2002-04       Impact factor: 31.745

8.  A critical role for IL-21 in regulating immunoglobulin production.

Authors:  Katsutoshi Ozaki; Rosanne Spolski; Carl G Feng; Chen-Feng Qi; Jun Cheng; Alan Sher; Herbert C Morse; Chengyu Liu; Pamela L Schwartzberg; Warren J Leonard
Journal:  Science       Date:  2002-11-22       Impact factor: 47.728

9.  Migratory properties of naive, effector, and memory CD8(+) T cells.

Authors:  W Weninger; M A Crowley; N Manjunath; U H von Andrian
Journal:  J Exp Med       Date:  2001-10-01       Impact factor: 14.307

10.  Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells.

Authors:  Andrea L Wurster; Vikki L Rodgers; Abhay R Satoskar; Matthew J Whitters; Deborah A Young; Mary Collins; Michael J Grusby
Journal:  J Exp Med       Date:  2002-10-07       Impact factor: 14.307

View more
  206 in total

Review 1.  Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

Authors:  Richard Wu; Marie-Andrée Forget; Jessica Chacon; Chantale Bernatchez; Cara Haymaker; Jie Qing Chen; Patrick Hwu; Laszlo G Radvanyi
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

Review 2.  Wnt/beta-catenin signaling in T-cell immunity and cancer immunotherapy.

Authors:  Luca Gattinoni; Yun Ji; Nicholas P Restifo
Journal:  Clin Cancer Res       Date:  2010-08-05       Impact factor: 12.531

Review 3.  Early events governing memory CD8+ T-cell differentiation.

Authors:  Joshua J Obar; Leo Lefrançois
Journal:  Int Immunol       Date:  2010-05-26       Impact factor: 4.823

4.  IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors.

Authors:  Lauren Giuffrida; Kevin Sek; Melissa A Henderson; Imran G House; Junyun Lai; Amanda X Y Chen; Kirsten L Todd; Emma V Petley; Sherly Mardiana; Izabela Todorovski; Emily Gruber; Madison J Kelly; Benjamin J Solomon; Stephin J Vervoort; Ricky W Johnstone; Ian A Parish; Paul J Neeson; Lev M Kats; Phillip K Darcy; Paul A Beavis
Journal:  Mol Ther       Date:  2020-07-21       Impact factor: 11.454

Review 5.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 6.  Human cell-based artificial antigen-presenting cells for cancer immunotherapy.

Authors:  Marcus O Butler; Naoto Hirano
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 7.  Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy.

Authors:  Joseph G Crompton; Madhusudhanan Sukumar; Nicholas P Restifo
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

8.  IL2Rβ-dependent signals drive terminal exhaustion and suppress memory development during chronic viral infection.

Authors:  Jean-Christophe Beltra; Sara Bourbonnais; Nathalie Bédard; Tania Charpentier; Moana Boulangé; Eva Michaud; Ines Boufaied; Julie Bruneau; Naglaa H Shoukry; Alain Lamarre; Hélène Decaluwe
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-29       Impact factor: 11.205

9.  Ikaros imposes a barrier to CD8+ T cell differentiation by restricting autocrine IL-2 production.

Authors:  Shaun O'Brien; Rajan M Thomas; Gerald B Wertheim; Fuqin Zhang; Hao Shen; Andrew D Wells
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

Review 10.  Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?

Authors:  Christopher A Klebanoff; Luca Gattinoni; Nicholas P Restifo
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.